Quality Systems

Articles

India's drug pricing authority increased the retail costs of certain domestically manufactured drugs, but not those of imported drug products. Pharma is asking why.

Report from India

India has the potential to become the new star of the biotechnology industry.

India's Biotech Industry is Poised for Exponential Growth

Jim Miller is president of PharmSource Information Services, Inc., and publisher of Bio/Pharmaceutical Outsourcing Report.

Indian manufacturers are not a near-term threat to Western CMOs, but may be long term.

A First Hand Look at India's Pharma Services Sector

Jane Wan is a freelance writer based in Singapore.

The contract-research industry in China is growing in leaps and bounds, and Big Pharma is leading the way.

Report From China

Stephanie Sutton was an assistant editor at Pharmaceutical Technology Europe.

Ongoing Free Trade Agreement (FTA) negotiations between the EU and India have hit a hurdle as some stakeholders urge the Indian government to fight against certain provisions in the FTA amid fears that access to generic drugs may be affected.

EU–India FTA Dispute Continues

A First-Hand Look at India's Pharma Services Sector

Brazil develops its first national plasma fractionation plant.

Report From Brazil March 2011

Nathan Jessop is a columnist for Pharmaceutical Technology Europe.

The recent India–EU summit was expected to bring news about the upcoming Free Trade Agreement between the EU and India; however, a dispute regarding the supply of generic drugs from India to developing countries has taken centre stage.

Generics Dispute EU-India Trade Negotiations

India is set to become a "biosimilar powerhouse", with manufacturers in this country well placed to capitalize on the growing biosimilars market, according to market analysts at Datamonitor.

India To Become A Biosimilar Powerhouse

As biologic-drug patents move toward expiration in the US, Indian firms with experience in the follow-on biologics arena are eager to partner with global manufacturers and secure their place in the growing biosimilars market.

Regulatory/GMP Compliance, Emerging Markets